Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2025 02:32 ET | Source: Recordati

RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER

NEWS RELEASE Milan, 23 October 2025 – Recordati, a global pharmaceutical company, announces today that Mike McClellan will join as its new Chief Financial Officer (CFO) as of January 1, 2026 and...
October 21, 2025 08:49 ET | Source: Recordati

Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology

The 2026 Award is focused on research in paediatric oncology, specifically sarcomasPaediatric sarcomas are among the leading causes of cancer-related death in children, yet there has been little...
July 29, 2025 12:13 ET | Source: Recordati

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%

Consolidated net revenue of € 1,323.8 million in the first half of 2025, +11.7% or +7.8% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 496.3 million, +9.6%, margin on...
June 24, 2025 07:05 ET | Source: Recordati

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE Vazkepa® supported by strong clinical data package and expected to contribute to...
May 08, 2025 06:25 ET | Source: Recordati

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

Consolidated net revenue of € 680.0 million in the first quarter of 2025, +11.9% or +7.2% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 270.2 million, +10.7%, margin...
April 28, 2025 13:18 ET | Source: Recordati

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND €...
April 16, 2025 04:34 ET | Source: Recordati

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME ISTURISA® is a cortisol synthesis inhibitor...
February 13, 2025 06:40 ET | Source: Recordati

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4%PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS Consolidated net revenue...
November 08, 2024 06:09 ET | Source: Recordati

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

Consolidated net revenue of € 1,743.1 million in the first nine months, +12.0% or +9.3% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 665.7 million, +11.8%, revenue...
October 04, 2024 05:07 ET | Source: Recordati

レコルダティ、エジャイモ®のグローバル権利取得に合意し、希少疾患事業を強化

レコルダティ、エジャイモ®のグローバル権利取得に合意し、希少疾患事業を強化ミラノ、2024年10月4日 – レコルダティは本日、サノフィとエジャイモ®（スチムリマブ）のグローバル権利を取得する契約を締結したことを発表しました。エジャイモ®は、寒冷凝集素症（CAD: Cold Agglutinin Disease）という希少なB細胞リンパ増殖性疾患の治療において唯一承認された生物学的製剤です。 ...